Boston Scientific Corporation (NYSE:BSX) stock is trading lower after the company cut its fiscal 2026 outlook, citing pressures on the Watchman and EP markets.
Q2 Beats Estimates
The medical technology giant reported revenues of $5.442 billion on Wednesday, better than the consensus estimate of $5.361 billion, beating the management guidance of $5.34 billion-$5.44 billion.
The medical devices maker reported adjusted earnings of 86 cents, beating the consensus of 83 cents and the management guidance of 82-84 cents.
“Our team delivered a solid quarter while continuing to navigate a dynamic environment,” said Mike Mahoney, chairman and CEO of Boston Scientific. “We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities…”
